Pharvaris (NASDAQ:PHVS) Price Target Raised to $75.00

Pharvaris (NASDAQ:PHVS) had its price target upped by Citizens Jmp from $74.00 to $75.00 in a research note released on Thursday,Benzinga reports. Citizens Jmp currently has a market outperform rating on the stock.

Several other brokerages have also commented on PHVS. Guggenheim boosted their price target on shares of Pharvaris from $39.00 to $40.00 and gave the stock a “buy” rating in a report on Thursday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Pharvaris in a research note on Friday, July 17th. HSBC raised shares of Pharvaris to an “overweight” rating in a research report on Thursday. HC Wainwright restated a “buy” rating on shares of Pharvaris in a research report on Tuesday, June 16th. Finally, Wall Street Zen lowered shares of Pharvaris from a “hold” rating to a “sell” rating in a research note on Saturday, July 18th. One research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $51.08.

Pharvaris Trading Up 3.2%

NASDAQ PHVS opened at $35.14 on Thursday. The company has a fifty day simple moving average of $33.71 and a two-hundred day simple moving average of $30.09. The stock has a market cap of $2.30 billion, a P/E ratio of -11.52 and a beta of -2.31. Pharvaris has a 12-month low of $20.65 and a 12-month high of $36.93.

Pharvaris (NASDAQ:PHVS) last posted its quarterly earnings data on Wednesday, August 12th. The company reported ($0.81) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.06). As a group, sell-side analysts forecast that Pharvaris will post -3.08 earnings per share for the current year.

Insider Activity at Pharvaris

In other Pharvaris news, CFO David W. Nassif sold 10,000 shares of Pharvaris stock in a transaction that occurred on Thursday, May 21st. The shares were sold at an average price of $30.31, for a total value of $303,100.00. Following the completion of the sale, the chief financial officer directly owned 120,300 shares of the company’s stock, valued at approximately $3,646,293. The trade was a 7.67% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Anne Lesage sold 30,703 shares of the stock in a transaction on Tuesday, June 30th. The stock was sold at an average price of $35.49, for a total value of $1,089,649.47. Following the transaction, the insider directly owned 93,969 shares in the company, valued at approximately $3,334,959.81. This represents a 24.63% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 158,322 shares of company stock valued at $5,371,886 in the last ninety days. 11.84% of the stock is owned by insiders.

Institutional Trading of Pharvaris

Hedge funds have recently added to or reduced their stakes in the business. GF Fund Management CO. LTD. purchased a new position in shares of Pharvaris during the 4th quarter worth about $35,000. Quantbot Technologies LP purchased a new stake in Pharvaris in the second quarter valued at approximately $41,000. JPMorgan Chase & Co. increased its position in Pharvaris by 30.6% during the second quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock worth $59,000 after purchasing an additional 783 shares during the last quarter. Barclays PLC acquired a new position in Pharvaris during the fourth quarter worth approximately $77,000. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new position in Pharvaris during the fourth quarter worth approximately $86,000.

Pharvaris Company Profile

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.